AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH). Specifically, it corresponds to amino acids 176–191 of the hGH sequence — the region responsible for hGH's fat-metabolizing (lipolytic) activity — without the growth-promoting or insulin-desensitizing effects of full-length hGH. This makes AOD-9604 a highly targeted metabolic peptide with a favorable safety profile.
Background & Development
AOD-9604 was originally developed by Monash University (Australia) and licensed to Metabolic Pharmaceuticals Ltd. It completed Phase IIb clinical trials for obesity treatment and received GRAS (Generally Recognized as Safe) status from the FDA in 2014 for use as a food ingredient. While it did not advance to Phase III trials for obesity (due to modest weight loss in heterogeneous populations), it remains widely used in integrative and sports medicine for body composition optimization.
Root Causes of Metabolic Fat Accumulation AOD-9604 Addresses
1. Impaired Growth Hormone Pulsatility
GH secretion declines with age (somatopause), obesity, insulin resistance, and chronic stress. Reduced GH pulsatility impairs lipolysis — particularly in visceral and subcutaneous adipose tissue. AOD-9604 mimics the lipolytic action of GH without requiring intact GH axis function.
2. Adipocyte Dysfunction & Lipid Trapping
In metabolic syndrome and obesity, adipocytes become hypertrophic and resistant to lipolytic signals. Beta-adrenergic receptor downregulation, elevated insulin, and chronic inflammation all impair fat mobilization. AOD-9604 directly stimulates lipolysis through GH receptor-independent mechanisms.
3. Reduced Fat Oxidation Capacity
Mitochondrial dysfunction, sedentary lifestyle, and low thyroid function reduce the capacity to oxidize mobilized fatty acids. AOD-9604 not only mobilizes fat but appears to enhance fat oxidation pathways, making it more effective than simple lipolytic agents.
4. Insulin Resistance & Hyperinsulinemia
Elevated insulin is the primary anti-lipolytic hormone — it suppresses hormone-sensitive lipase (HSL) and promotes fat storage. Unlike full-length hGH, AOD-9604 does not worsen insulin sensitivity, making it suitable for metabolically compromised patients.
5. Cartilage & Joint Degeneration (Secondary Indication)
Emerging research suggests AOD-9604 has chondroprotective and regenerative properties — stimulating proteoglycan synthesis and reducing cartilage degradation. This positions it as a dual-purpose peptide for body composition and musculoskeletal health.
Mechanisms of Action
Lipolysis Stimulation
AOD-9604 binds to a specific receptor on adipocytes (distinct from the full GH receptor) and activates beta-3 adrenergic-like signaling pathways. This activates hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL), releasing stored triglycerides as free fatty acids (FFAs) for oxidation. The effect is particularly pronounced in visceral adipose tissue.
Inhibition of Lipogenesis
AOD-9604 inhibits the conversion of non-fat foods into body fat (lipogenesis) by downregulating fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) — key enzymes in de novo lipogenesis. This dual action (stimulate lipolysis + inhibit lipogenesis) makes it uniquely effective for fat loss.
No IGF-1 Stimulation
Unlike full-length hGH or GH secretagogues (ipamorelin, CJC-1295), AOD-9604 does not stimulate IGF-1 production. This means no growth-promoting effects, no insulin resistance, no cell proliferation concerns, and no suppression of endogenous GH axis — a critical safety advantage.
Cartilage Regeneration
In vitro and animal studies demonstrate AOD-9604 stimulates chondrocyte proliferation and proteoglycan synthesis while inhibiting matrix metalloproteinases (MMPs) that degrade cartilage. Human clinical data is limited but promising for osteoarthritis applications.
Metabolic Flexibility Enhancement
AOD-9604 appears to improve the metabolic switch between glucose and fat oxidation — a key marker of metabolic health. This may be mediated through AMPK activation and PGC-1α upregulation, promoting mitochondrial biogenesis and fat oxidation capacity.
Clinical Evidence
Phase II Clinical Trials
The METAOD trials (Phase IIa/IIb) evaluated AOD-9604 in overweight and obese adults:
- METAOD001/002: Demonstrated significant fat mass reduction vs. placebo at 12 weeks with subcutaneous dosing
- METAOD003: Oral formulation showed modest but statistically significant weight loss
- METAOD005: Larger Phase IIb trial showed variable results across heterogeneous populations; primary endpoint not met for oral formulation at standard doses
Key finding: subcutaneous administration consistently outperformed oral in fat loss outcomes. The oral bioavailability challenges led to the Phase III decision not to proceed for obesity as a primary indication.
Safety Profile
Across all clinical trials, AOD-9604 demonstrated an excellent safety profile:
- No significant adverse events vs. placebo
- No effect on blood glucose or insulin levels
- No effect on IGF-1 levels
- No suppression of endogenous GH secretion
- No cardiovascular, hepatic, or renal toxicity signals
Clinical Protocols & Dosing
Standard Dosing — Subcutaneous Injection
- Dose: 250–500 mcg per day
- Timing: Fasted state — ideally upon waking, 30–60 minutes before eating or exercise
- Frequency: Daily or 5 days on / 2 days off
- Cycle length: 8–16 weeks; can be used continuously given favorable safety profile
- Injection site: Subcutaneous — abdomen, thigh, or deltoid
Oral Dosing
- Dose: 1–2 mg/day (oral bioavailability is significantly lower than SQ)
- Timing: Fasted state
- Note: Oral formulations are less studied and less reliable; SQ is preferred for clinical outcomes
Combination Protocols
AOD-9604 is frequently combined with other peptides for synergistic effects:
- AOD-9604 + CJC-1295/Ipamorelin: AOD provides targeted lipolysis; CJC/Ipamorelin provides GH pulse for muscle preservation and recovery. A highly popular body recomposition stack.
- AOD-9604 + Semaglutide/GLP-1 RA: GLP-1 RA reduces appetite and caloric intake; AOD enhances fat mobilization. Addresses the muscle-loss concern of GLP-1 RAs by preserving metabolic rate.
- AOD-9604 + BPC-157: For athletes — AOD for fat loss, BPC-157 for tissue repair and recovery.
- AOD-9604 + MOTS-c: Dual mitochondrial and lipolytic support for metabolic syndrome and aging-related fat accumulation.
Timing Optimization
- Administer in a fasted state to maximize lipolytic effect (insulin suppresses AOD-9604 activity)
- Pre-workout administration (30–60 min before training) enhances fat oxidation during exercise
- Avoid administration within 2 hours of carbohydrate-containing meals
Integrative Protocols: Maximizing AOD-9604 Outcomes
Dietary Strategy
- Protein-forward diet: 1.6–2.0 g/kg body weight to preserve lean mass during fat loss
- Carbohydrate timing: Concentrate carbohydrates around training; minimize fasted-state carbohydrate intake to maintain lipolytic environment
- Intermittent fasting: 16:8 or 18:6 protocols synergize with AOD-9604 by extending the fasted lipolytic window
- Avoid chronic caloric restriction: Severe restriction reduces metabolic rate and blunts AOD-9604 effectiveness; moderate deficit (300–500 kcal) is optimal
Exercise Protocol
- Fasted cardio: Low-to-moderate intensity cardio in the fasted state (post-AOD administration) maximizes fat oxidation
- Resistance training: Essential for preserving lean mass and maintaining metabolic rate during fat loss
- HIIT: High-intensity intervals post-AOD administration enhance AMPK activation and fat oxidation
Supportive Supplements
- L-Carnitine: 2–3 g/day — shuttles mobilized FFAs into mitochondria for oxidation; directly synergistic with AOD-9604
- Alpha-Lipoic Acid (R-ALA): 300–600 mg/day — enhances insulin sensitivity and mitochondrial fat oxidation
- Berberine: 500 mg 2–3x/day — AMPK activator; synergizes with AOD-9604 for metabolic flexibility
- Omega-3 fatty acids: 2–4 g EPA+DHA/day — reduce adipose inflammation and improve lipolytic signaling
- Magnesium glycinate: 300–400 mg/day — supports insulin sensitivity and mitochondrial function
Monitoring
- Body composition (DEXA or bioimpedance) at baseline and every 4–8 weeks
- Fasting glucose, insulin, HOMA-IR
- Lipid panel (expect improvement in triglycerides and HDL)
- IGF-1 (should remain unchanged — confirms no GH axis stimulation)
- Liver enzymes (ALT/AST) — baseline safety
Contraindications & Precautions
- Active malignancy: As with all growth-related peptides, use with caution; however, AOD-9604's lack of IGF-1 stimulation significantly reduces theoretical proliferative risk
- Pregnancy and breastfeeding: Insufficient safety data; avoid
- Insulin-dependent diabetes: Monitor closely; AOD-9604 does not affect insulin but fat mobilization may alter glucose dynamics
- Thyroid dysfunction: Hypothyroidism impairs fat oxidation; optimize thyroid function before or alongside AOD-9604 therapy
AOD-9604 vs. Full-Length hGH: Key Distinctions
- AOD-9604 provides targeted lipolysis without growth promotion, IGF-1 stimulation, or insulin resistance
- No water retention (common with hGH)
- No carpal tunnel syndrome or joint pain (common hGH side effects)
- No suppression of endogenous GH axis
- Significantly lower cost and regulatory burden than pharmaceutical hGH
- GRAS status (FDA) — unique among peptides
Key Takeaways
- AOD-9604 is the C-terminal fragment of hGH responsible for lipolysis — without the growth-promoting or metabolic side effects of full-length hGH
- It stimulates lipolysis and inhibits lipogenesis through adipocyte-specific receptor signaling
- Excellent clinical safety profile with GRAS status — one of the safest peptides in the metabolic category
- Most effective when administered fasted, combined with resistance training and adequate protein
- Synergizes powerfully with GLP-1 RAs (addresses muscle loss), CJC-1295/Ipamorelin (body recomposition), and MOTS-c (metabolic flexibility)
- Emerging evidence supports cartilage regeneration as a secondary indication
0 comments